Acquisition Announced
Merck & Co. acquisition of Terns Pharmaceuticals
US$6.7bn equity value
Announced 24 Mar 2026 · US$53.00 cash per share
Advisers
Terns Pharmaceuticals
Target
- Financial adviser
- Legal adviser
Merck & Co.
Acquirer
- Legal adviser
- Target
- Terns Pharmaceuticals
- Acquirer
- Merck & Co.
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
Sources
- 2026 Centerview Partners: Lead financial advisor to Terns Pharmaceuticals on its sale to Merck centerviewpartners.com
- 25 Mar 2026 Freshfields Advises Terns Pharmaceuticals in $6.7bn Acquisition by Merck freshfields.com
- 25 Mar 2026 Gibson Dunn Antitrust Team Advises Merck on $6.7 Billion Acquisition of Terns Pharmaceuticals, Inc. gibsondunn.com
- 7 Apr 2026 Tender offer statement (SC TO-T), Terns Pharmaceuticals, Inc. sec.gov
- 7 Apr 2026 Target response to tender offer (SC 14D9), Terns Pharmaceuticals, Inc. sec.gov



